ORIC Pharmaceuticals (ORIC) analyst forecast and price target
Analyst forecast
Consensus of 15 analyst ratings
Based on 4 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| JP Morgan | Maintained | Overweight | $26.00 from $23.00 | Oct 14, 2026 |
| Leerink Partners | Initiated Coverage | Outperform | $26.00 | Oct 5, 2026 |
| BTIG | Initiated Coverage | Buy | $26.00 | Sep 23, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $27.00 from $25.00 | Aug 10, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $25.00 | Jun 8, 2026 |
| Citigroup | Maintained | Buy | $16.00 from $17.00 | May 5, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $25.00 | Apr 2, 2026 |
| Wedbush | Maintained | Outperform | $17.00 from $20.00 | Apr 1, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $25.00 | Mar 13, 2026 |
| Wedbush | Maintained | Outperform | $20.00 | Feb 24, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $25.00 from $23.00 | Feb 24, 2026 |
| Citigroup | Maintained | Buy | $17.00 from $16.00 | Feb 24, 2026 |
| Wedbush | Maintained | Outperform | $20.00 | Jan 13, 2026 |
| Piper Sandler | Initiated Coverage | Overweight | $22.00 | Jan 7, 2026 |
| Wedbush | Maintained | Outperform | $20.00 | Dec 8, 2025 |
| Wells Fargo | Maintained | Overweight | $25.00 from $19.00 | Dec 8, 2025 |
| Evercore ISI Group | Initiated Coverage | Outperform | $25.00 | Nov 20, 2025 |
| JP Morgan | Maintained | Overweight | $20.00 from $17.00 | Nov 18, 2025 |
| Wolfe Research | Initiated Coverage | Peer Perform | — | Nov 18, 2025 |
| Citigroup | Maintained | Buy | $16.00 from $12.00 | Nov 17, 2025 |
Frequently asked questions
What is the price target for ORIC stock?
The average 12-month analyst price target for ORIC Pharmaceuticals (ORIC) is $26.25, with a high estimate of $27.00 and a low of $26.00, across 4 analysts.
Is ORIC a buy, sell, or hold?
Analysts covering ORIC Pharmaceuticals currently average a Buy rating: 14 buy, 1 hold and 0 sell, from 15 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for ORIC?
The average price target of $26.25 implies 126.49% upside from the last price of $11.59.
What is the latest analyst rating on ORIC?
On Oct 14, 2026, JP Morgan maintained ORIC Pharmaceuticals at Overweight with a price target of $26.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.